Amgen Establishes Commercial Operations in Brazil

Thousand Oaks, California (ots/PRNewswire) - Amgen , the
world's largest biotechnology company, announced today the expansion
of its operations in Brazil, including the acquisition of Bergamo, a
privately-held Brazilian pharmaceutical company. Amgen has also
agreed to reacquire rights in Brazil to its products that were
previously granted to Mantecorp (subsequently acquired by
Hypermarcas). Together, these transactions will provide Amgen a
significant presence in Brazil and immediate, direct access to one of
the fastest growing pharmaceutical markets in the world.

Bergamo is a leading supplier of medicines to the hospital sector
in Brazil with capabilities in oncology medicines and has
manufacturing facilities in Sao Paulo state. Bergamo had gross
revenues of US $80 million in 2010 and has been growing at an annual
rate of 19 percent since 2007. Under terms of the transaction
announced today, Amgen gained full ownership of Bergamo by purchasing
it for approximately US $215 million.

Amgen has entered into an agreement in principle with Hypermarcas
to reacquire the rights in Brazil to several of Amgen's innovative
medicines, two of which are already approved in Brazil, Vectibix(R)
(panitumumab) and Mimpara(R) (cinacalcet), and a third, romiplostim,
(registered as Nplate(R) in the United States), a treatment for the
blood disorder ITP, which is currently under review by ANVISA, the
regulatory authority in Brazil.

"Amgen's strategic goal is to make our innovative medicines
available to patients in major markets around the world," said Kevin
Sharer, Amgen's chairman and chief executive officer. "Acquiring
Bergamo, a profitable company with an established local
infrastructure, and regaining the rights to our products in Brazil,
provides us an attractive entry into the Brazilian market."

The focus on Brazil is part of a wider international expansion
strategy for Amgen. Brazil is among the top 10 pharmaceutical markets
in the world and in recent years has been growing at a rate of about
12 percent per year. It is expected to be the world's fifth largest
pharmaceutical market by 2015.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative
human therapeutics. A biotechnology pioneer since 1980, Amgen was one
of the first companies to realize the new science's promise by
bringing safe, effective medicines from lab to manufacturing plant to
patient. Amgen therapeutics have changed the practice of medicine,
helping millions of people around the world in the fight against
cancer, kidney disease, rheumatoid arthritis, bone disease, and other
serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our
pioneering science and vital medicines, visit http://www.amgen.com.

Forward Looking Statements

This news release contains forward-looking statements that
involve significant risks and uncertainties, including those
discussed below and others that can be found in our Form 10-K for the
year ended Dec. 31, 2010, and in our periodic reports on Form 10-Q
and Form 8-K. Amgen is providing this information as of the date of
this news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. The Company's results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments (domestic or foreign) involving current and
future products, sales growth of recently launched products,
competition from other products (domestic or foreign), difficulties
or delays in manufacturing our products. In addition, sales of our
products are affected by reimbursement policies imposed by
third-party payors, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment as well as
U.S. legislation affecting pharmaceutical pricing and reimbursement.
Government and others' regulations and reimbursement policies may
affect the development, usage and pricing of our products.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted
by government investigations, litigation and products liability
claims. Further, while we routinely obtain patents for our products
and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors. We depend on third parties for a significant portion of
our manufacturing capacity for the supply of certain of our current
and future products and limits on supply may constrain sales of
certain of our current products and product candidate development. In
addition, we compete with other companies with respect to some of our
marketed products as well as for the discovery and development of new
products. Discovery or identification of new product candidates
cannot be guaranteed and movement from concept to product is
uncertain; consequently, there can be no guarantee that any
particular product candidate will be successful and become a
commercial product. Further, some raw materials, medical devices and
component parts for our products are supplied by sole third-party
suppliers.

Contact, Amgen
Mary Klem, +1-805-447-6979 (U.S. media)
Helen Mills, +41-41-3690-315 (EU media)
Shirley Emerick +55-11-8924-8608 (Brazil media)
Arvind Sood, +1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

ots Originaltext: Amgen
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.